5 completed, 1 terminated, 1 unknown, 1 withdrawn. 2 Phase 2, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Not applicable | 1 | Unknown 1 |
| Phase 3 | 1 | Terminated 1 |
Follow SARS (Disease): new trials by email Literature Review of SARS (Disease) trials Research Report on SARS (Disease)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Characteristics of Patients With COVID-19 in Meta State, Colombia COVID, SARS-CoV 2 | Withdrawn | Hospital Departamental de Villavicencio | 2021-09-01 | 2023-07-05 | ||
| Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants BNT162b2, Multivalent BNT162b2 (B.1.1.7 + B.1.617.2), Monovalent BNT162b2 (B.1.1.7) - SARS-CoV-2 Infection, COVID-19 | Phase 2 | Completed | BioNTech SE | 1380 | 2021-08-25 | 2024-11-22 |
| Efficacy of Montelukast in Mild-moderate Respiratory Symptoms in Patients With Long-COVID-19: Montelukast, placebo - Covid19, SARS (Disease) | Phase 3 | Terminated | Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina | 86 | 2021-08-11 | 2024-07-03 |
| Follow-up of Covid-19 Long Term Sequelae Not applicable (observational study) - COVID-19 Pneumonia, COVID-19 Respiratory Infection | Completed | Azienda Ospedaliera Universitaria Integrata Verona | 7599 | 2021-04-16 | 2024-10-28 | |
| COVAG - Covid-19 Antigen Study - the Diagnostic Efficacy of SARS-CoV-2 Rapid Detection Tests 3 nasopharyngeal swab - COVID-19, SARS-CoV2 Infection | Completed | Synlab Holding Deutschland GmbH | 2222 | 2021-02-01 | 2021-10-20 | |
| Cyclosporine For The Treatment Of COVID-19(+) Cyclosporine, Standard of Care Treatment - SARS (Disease) | Phase 2 | Completed | Bryan Burt, MD | 47 | 2020-11-23 | 2023-07-20 |
| Inhaled Ibuprofen to Treat COVID-19 Inhaled Hypertonic ibuprofen - Coronavirus Infection, Respiratory Disease | Not applicable | Unknown | Química Luar SRL | 40 | 2020-05-01 | 2020-06-11 |
| Assessment of the Psycho-social Impact of COVID-19 Outbreak COM-COVID anonimous survey - SARS-CoV 2, COVID-19 | Completed | Fundació Institut Germans Trias i Pujol | 56656 | 2020-03-31 | 2023-07-10 |
Disease (8) · Severe Acute Respiratory Syndrome (8) · COVID-19 (6) · Coronavirus Infections (3) · Communicable Diseases (1) · Pneumonia, Viral (1) · Psychological Well-Being (1) · Respiration Disorders (1)
Coronaviridae Infections (8) · Infections (8) · Nidovirales Infections (8) · Pathologic Processes (8) · Pathological Conditions, Signs and Symptoms (8) · RNA Virus Infections (8) · Respiratory Tract Diseases (8) · Respiratory Tract Infections (8) · Virus Diseases (8) · Lung Diseases (7) · Pneumonia (7) · Pneumonia, Viral (6) · Coronavirus Infections (5) · Behavior (1) · Disease Attributes (1)
BNT162 Vaccine (1) · Cyclosporine (1) · Observation (1) · Watchful Waiting (1) · montelukast (1)
Azienda Ospedaliera Universitaria Integrata Verona (1) · BioNTech SE (1) · Bryan Burt, MD (1) · Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina (1) · Fundació Institut Germans Trias i Pujol (1) · Hospital Departamental de Villavicencio (1) · Química Luar SRL (1) · Synlab Holding Deutschland GmbH (1)
Spain (3) · Germany (2) · United States (2) · Argentina (1) · Belgium (1) · France (1) · Italy (1) · Netherlands (1) · Republic of the Congo (1) · South Africa (1) · Turkey (Türkiye) (1)
Betlem Salvador Gonzalez, PhD (1) · Bryan Burt, MD (1) · Cris Vilaplana, MD, PhD (1) · Dante M Beltramo, PhD (1) · Evelina Tacconelli, Professor (1) · Francisco Mera Cordero, MD (1) · Jesus Almeda Ortega, PhD (1) · Norton Perez, MD (1) · Sara Bonet Monne, PhD (1)
PMID 17031779, PMID 29772761, PMID 31668196, PMID 32091533, PMID 32146445, PMID 32171076, PMID 32187459, PMID 32220207, PMID 32220208, PMID 32227758, PMID 32419926, PMID 34460083, PMID 34836903, PMID 34991703, PMID 36378074, PMID 37527039, PMID 37654668, PMID 39097927